

Table 1. Expression of B7-H1 in human tumor cell lines

Tissue origin	Cell line	Pathology	B7-H1 expression*	
			Medium	IFN- $\gamma^{**}$
Lung	SK-LU-1	Adenocarcinoma	-	-
	SK-MES-1	Squamous carcinoma	+	ND
	NCI-H292	Mucoepidermoid carcinoma	++	ND
	NCI-H128	Small cell carcinoma	-	-
	NCI-H69	Small cell carcinoma	-	-
	SCC-37	Small cell carcinoma	-	+
	SCC-9	Small cell carcinoma	-	-
	SCC-18	Small cell carcinoma	+	+
	SCC-117	Small cell carcinoma	++	ND
Ovary	CaOV3	Adenocarcinoma	++	ND
	NIH-OVCAR3	Adenocarcinoma	-	ND
	SK-OVCA3	Adenocarcinoma	-	++
Colon	SW620	Colorectal adenocarcinoma	-	+
	WiDr	Colorectal adenocarcinoma	-	+
	HT-29	Colorectal adenocarcinoma	-	++
Duodenum	HuTu 80	Adenocarcinoma	-	+
Leukemia	U937	Monocyte	-	+
lymphoma	K562	Erythromyeloblast	-	-
	Jurkat	T lymphocyte	-	-
	Molt 4	T lymphocyte	-	ND
	Raji	B lymphocyte	-	+
Placenta	JAR	Choriocarcinoma	-	+
	Bewo	Choriocarcinoma	-	-
Skin	SK-MEL-28	Melanoma	-	++
	HT-144	Metastatic melanoma	-	+
	624mel	Melanoma	-	-
	697mel	Melanoma	-	-

---

888mel	Melanoma	-	-
586mel	Melanoma	-	+

---

\* The expression of B7-H1 was determined by FACS analysis using anti-B7-H1 mAb.  
++: >50% positive, +: 10-50% positive, -: <10% positive, ND: not done.

\*\* Cells were incubated with 2,000 IU/ml of recombinant human IFN- $\gamma$  for 24-48 hours before FACS analysis.